promo_leaderboard Ad
‹ All stocks
AXSM

Axsome Therapeutics

AXSM · NASDAQ · Healthcare
$135.77
▼ $1.24 (-0.91%)
$127.93 $150.63 $173.33 $196.03 $135.77 Sep 2026 Oct 2026 Nov 2026
Day range
$134.76 – $137.25
Year range
$123.00 – $260.19
Open
$136.36
Previous close
$137.01
Market cap
$7.14B
Volume (24h)
$55.0K
Volume (52w)
$7.47M
Performance
7D
▼ -3.69%
1M
▼ -12.86%
3M
▼ -37.78%
6M
▼ -41.89%
1Y
▼ -6.73%
YTD
▼ -24.02%
3Y
▲ 126.13%
5Y
▲ 281.48%
All-time
▲ 1453.43%
Key statistics
P/E ratio
-42.30
EPS (TTM)
$-3.21
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
52.6M
About Axsome Therapeutics

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

Visit website
Country: United States of America
Related news
More in Healthcare